Application of pharmacogenetics: UGT1A1*28 and nilotinib-induced unconjugated hyperbilirubinaemia in a patient with chronic myeloid leukaemia

Pathology. 2011 Apr;43(3):273-4. doi: 10.1097/PAT.0b013e328343f0b4.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Bilirubin / blood
  • Genetic Predisposition to Disease
  • Glucuronosyltransferase / genetics*
  • Humans
  • Hyperbilirubinemia / chemically induced*
  • Hyperbilirubinemia / genetics
  • Hyperbilirubinemia / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Male
  • Molecular Diagnostic Techniques
  • Pharmacogenetics
  • Polymorphism, Single Nucleotide
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrimidines / adverse effects*
  • Pyrimidines / pharmacokinetics

Substances

  • Pyrimidines
  • UGT1A1 enzyme
  • Glucuronosyltransferase
  • Protein-Tyrosine Kinases
  • nilotinib
  • Bilirubin